Authors

Harold P. Freeman, MD

Latest:

Dr. Freeman Describes Patient Navigation

Dr. Harold P. Freeman from Ralph Lauren Center for Cancer Care and Prevention Describes Patient Navigation

Harriet Kluger, MD

Latest:

Dr Kluger on the FDA Approval of Lifileucel in Advanced Melanoma

Harriet Kluger, MD, discusses the FDA approval of the tumor infiltrating lymphocyte therapy lifileucel for patients with advanced melanoma.

Harry Erba, MD, PhD

Latest:

The Role of Genetic Profiling in Secondary AML

James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.

Harry P. Erba, MD, PhD, Duke Cancer Institute

Latest:

Treatment Approaches for TP53-Mutated AML

Key opinion leaders in hematology oncology share insights into the challenges associated with treating patients with TP53-mutated AML and highlight the recent FDA breakthrough designation of eprenetapopt.

Harry Erba, MD, PhD, Duke University

Harry Erba, MD, PhD, University of Alabama

Harry Erba, MD, PhD, University of Alabama at Birmingham

Harry H. Yoon, MD

Latest:

A Look Towards the Future of ESCC

Closing out their conversation, Drs Saba and Yoon share their hopes for the future of ESCC, including elucidating the molecular mechanisms behind immune evasion and treatment response to chemotherapy, radiation, and immunotherapy.

Harry P. Erba, MD, PhD, Duke University School of Medicine

Latest:

The Role of Venetoclax for Treatment of AML

Renowned experts in hematology-oncology provide insight into the practical implications of treating acute myeloid leukemia with the current standard-of-care regimen using venetoclax.

Harry P. Erba, MD, PhD, Duke University

Harry P. Erba, MD, PhD, UAB

Harry P. Erba, MD, PhD, University of Alabama

Harsha Ranganath, MD

Latest:

Dr. Ranganath on Treatment Considerations in Nonmetastatic Prostate Cancer

Harsha Ranganath, MD, a fellow in the Division of Hematology & Oncology at the University of Tennessee West Cancer Center, discusses treatment considerations in nonmetastatic prostate cancer.

Harvard Medical School

Harvey I. Pass, MD

Latest:

Dr. Harvey I. Pass on Personalized Surgical Approaches in Lung Cancer

Harvey I. Pass, MD, director, Thoracic Surgery, Thoracic Oncology, NYU Langone Medical Center, discusses what it means to take a personalized approach to surgery in lung cancer.

Hashem El-Serag, MD, MPH

Latest:

Dr. Hashem El-Serag on the Relationship Between NASH and HCC

Hashem El-Serag, MD, MPH, medicine-gastroenterology, Baylor College of Medicine, discusses the relationship between nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).

Hassane M. Zarour, MD

Latest:

Dr. Zarour on Unmet Needs in Melanoma

Hassane M. Zarour, MD, professor of medicine, University of Pittsburgh, discusses unmet needs in melanoma.

Hatem Soliman, MD

Latest:

Dr. Soliman the Utility of ADCs in Breast Cancer

Hatem Soliman, MD, discusses the utility of antibody-drug conjugates in breast cancer.

Hatem Soliman, MD, H. Lee Moffitt Cancer Center & Research Institute

Hatim Husain, MD

Latest:

Charting the Future: Key Therapies for Managing EGFR-Mutant NSCLC

This episode focuses on exploring additional therapeutic options for managing previously treated advanced or metastatic EGFR-mutated NSCLC, highlighting strategies to optimize patient survival across various stages of disease progression.